Iovance Biotherapeutics Inc

NASDAQ:IOVA

2.11

-0.53 (-20.08%)

7:58:20 PM EDT: $2.11 0.00 (-0.01%)

Market Cap (Intraday)	563.12M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$76.22 Million
Adjusted EPS	-$0.25

See more estimates

10-Day MA	$2.61
50-Day MA	$2.22
200-Day MA	$4.94

See more pivots

Iovance Biotherapeutics Inc Stock, NASDAQ:IOVA

825 Industrial Road, Suite 400, San Carlos, California 94070

United States of America

Phone: +1.650.260.7120

Number of Employees: 838

http://www.iovance.com

Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.